Literature DB >> 19450715

Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy.

G Favia1, G P Pilolli, E Maiorano.   

Abstract

INTRODUCTION: Patients undergoing bisphosphonate therapies may develop jaw lesions, mainly consisting in bone necrosis. No effective treatment has been proposed so far for such lesions, nor is there a uniform concept on the possible pathogenesis of this entity.
METHODS: The study population included 31 patients with bisphosphonate-related osteonecrosis of the jaws and 10 healthy donors. All patients underwent to jaw bone biopsy and the tissue samples were divided into two parts, one of which was fixed, decalcified and routinely processed. The second part was fixed, embedded in methylmetacrylate, cut and stained with methylene blue and basic fuchsine. All samples were subjected to light and confocal microscopic examination and to histomorphometric analyses to evaluate differences in bone structure between the two samples groups.
RESULTS: Three main histological patterns were identified in ONJ patients: 1 - Areas with active acute inflammation, characterized by predominance of soft tissues, inflammatory infiltrate, acellular necrotic debris, thin-walled and dilated blood vessel, intensely basophilic bone spiculae with scalloped borders showing prominent bone resorption. 2 - Areas characterized by predominance of bony structures showing wide acellular necrotic sequestra and large, scalloped Haversian canals containing inflammatory cells. 3 - Non-necrotic areas contained larger amounts of bone, showing increased trabecular thickness, inter-osteonic bone deposition and smaller and fewer Haversian canals. These differences were more evident after comparing the histomorphometrical data of samples from ONJ patients with controls. Also, lamellar bone from treated patients was composed of bigger osteones containing larger osteocytes. Two different types of newly-formed woven bone, mainly showing centrifugal spatial orientation, were easily detectable in these areas. Osteoclast-like cells detected in inflammatory areas from treated patients were small and contained few nuclei, but they were rare to absent in non-necrotic bone from the same patients.
CONCLUSIONS: These features point at a peculiar process of bone remodeling in patients undergoing bisphosphonate therapy, which showed scarce osteoclastic activity and subsequent deposition of newly-formed bone. The latter would be made up of thicker bone structures supplied by fewer blood vessels. Consequently, in case of increased metabolic requests, this modified bone would not be supported by adequate blood supply, thus leading to necrosis and superinfection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19450715     DOI: 10.1016/j.bone.2009.05.008

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  35 in total

Review 1.  Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: case report and literature review.

Authors:  Sabrina Crépin; Marie-Laure Laroche; Bernard Sarry; Louis Merle
Journal:  Eur J Clin Pharmacol       Date:  2010-05-01       Impact factor: 2.953

Review 2.  Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review.

Authors:  Cesar A Migliorati; Joel B Epstein; Elliot Abt; James R Berenson
Journal:  Nat Rev Endocrinol       Date:  2010-11-16       Impact factor: 43.330

3.  Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons.

Authors:  Toshiyuki Yoneda; Hiroshi Hagino; Toshitsugu Sugimoto; Hiroaki Ohta; Shunji Takahashi; Satoshi Soen; Akira Taguchi; Satoru Toyosawa; Toshihiko Nagata; Masahiro Urade
Journal:  J Bone Miner Metab       Date:  2010-03-24       Impact factor: 2.626

Review 4.  Use of bisphosphonates and the risk of osteonecrosis among cancer patients: a systemic review and meta-analysis of the observational studies.

Authors:  Si-Huei Lee; Rai-Chi Chan; Shy-Shin Chang; Yin-Ling Tan; Kai-Hsiang Chang; Matthew C Lee; Huai-En Chang; Chien-Chang Lee
Journal:  Support Care Cancer       Date:  2013-11-08       Impact factor: 3.603

Review 5.  Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.

Authors:  Peter K Wong; Gelsomina L Borromeo; John D Wark
Journal:  Rheumatol Int       Date:  2013-05-08       Impact factor: 2.631

6.  Macrophages and bisphosphonate-related osteonecrosis of the jaw (BRONJ): evidence of local immunosuppression of macrophages in contrast to other infectious jaw diseases.

Authors:  Sebastian Hoefert; Inge Schmitz; Frank Weichert; Marcel Gaspar; Harald Eufinger
Journal:  Clin Oral Investig       Date:  2014-06-24       Impact factor: 3.573

Review 7.  Osteochemonecrosis: an overview.

Authors:  John Hellstein
Journal:  Head Neck Pathol       Date:  2014-11-20

8.  Comparative assessment of the interfacial soft and hard tissues investing implants and natural teeth in the macaque mandible.

Authors:  Chong Huat Siar; Chooi Gait Toh; Georgios E Romanos; Kok Han Ng
Journal:  Clin Oral Investig       Date:  2014-11-21       Impact factor: 3.573

9.  Osteo-radio-necrosis (ORN) and bisphosphonate-related osteonecrosis of the jaws (BRONJ): the histopathological differences under the clinical similarities.

Authors:  Konstantinos T Mitsimponas; Patrick Moebius; Kerstin Amann; Philipp Stockmann; Karl-Andreas Schlegel; Friedrich-Wilhelm Neukam; Falk Wehrhan
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

10.  Expression of Msx-1 is suppressed in bisphosphonate associated osteonecrosis related jaw tissue-etiopathology considerations respecting jaw developmental biology-related unique features.

Authors:  Falk Wehrhan; Peter Hyckel; Jutta Ries; Phillip Stockmann; Emeka Nkenke; Karl A Schlegel; Friedrich W Neukam; Kerstin Amann
Journal:  J Transl Med       Date:  2010-10-13       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.